During xLAB’s Founder Master’s research, she was determined to tackle a stubborn problem—late diagnosis of cervical cancer among Kenyan women. Cervical cancer, primarily caused by HPV 16 and 18, remains the second most common cancer in women in Kenya. Yet screening rates are painfully low, and the tests available are either too complex, costly, or require advanced lab infrastructure not widely accessible in our settings.
✨ This led to the development of a paper-based nanokit that enhances early detection of HPV 16/18 E6 oncoproteins—a biomarker highly specific for cervical cancer progression. Through nanotechnology and a dot blot molecular assay, the kit demonstrated:
✔️ 90% sensitivity and specificity
✔️ Extremely low detection limit (0.0005 pg/ml)
✔️ Fast, accurate, and field-adaptable testing
This innovation isn’t just academic—it’s deeply personal. It’s a building block in our mission to redefine how we detect, treat, and talk about STIs and reproductive health in Africa. Through xLAB Diagnostics Africa, we’re scaling these kinds of insights into real-world solutions—like the X-Pack (a home STI test kit) and community-led screening approaches. Because science must move beyond the lab and into lives. 📣 To researchers: Your work has power beyond publication. It can save lives. To funders, policymakers, and community leaders: Let’s invest in homegrown innovations that meet people where they are—with dignity, privacy, and precision.
📌 Learn more about the study here: [DOI: https://doi.org/10.33696/Nanotechnol.1.006]
#CervicalCancerAwareness #HPV #WomensHealth #xLABDiagnostics #Nanotechnology

